BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Younossi ZM, Stepanova M, Ong J, Trimble G, AlQahtani S, Younossi I, Ahmed A, Racila A, Henry L. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol 2021;19:580-589.e5. [PMID: 32531342 DOI: 10.1016/j.cgh.2020.05.064] [Cited by in Crossref: 132] [Cited by in F6Publishing: 104] [Article Influence: 66.0] [Reference Citation Analysis]
Number Citing Articles
1 Dodge JL, Lee BT, Kassem ACZ, Biggins SW, Rana PA, Nadim MK, Asrani SK, Fong TL. The Conundrum of Patients With Compensated Cirrhosis Requiring Kidney Transplantation; Kidney Alone or Simultaneous Liver Kidney Transplantation. Transplantation 2023;107:429-37. [PMID: 36194998 DOI: 10.1097/TP.0000000000004311] [Reference Citation Analysis]
2 Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, Yilmaz Y, De Ledinghen V, Costentin C, Zheng MH, Wai-Sun Wong V, Elkhashab M, Huss RS, Myers RP, Roux M, Labourdette A, Destro M, Fournier-Poizat C, Miette V, Sandrin L, Boursier J. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores. J Hepatol 2023;78:247-59. [PMID: 36375686 DOI: 10.1016/j.jhep.2022.10.034] [Reference Citation Analysis]
3 Lundholm MD, Bena J, Zhou K, Tsushima Y, Kashyap SR. Prevalence and clinical determinants of non-alcoholic fatty liver disease by liver scores in adults with type 1 diabetes. J Diabetes Complications 2023;37:108405. [PMID: 36669324 DOI: 10.1016/j.jdiacomp.2023.108405] [Reference Citation Analysis]
4 Ma J, Deng Y, Yang T, Li M, Shang J. Esculetin Alleviates Nonalcoholic Fatty Liver Disease on High-Cholesterol-Diet-Induced Larval Zebrafish and FFA-Induced BRL-3A Hepatocyte. Int J Mol Sci 2023;24. [PMID: 36675107 DOI: 10.3390/ijms24021593] [Reference Citation Analysis]
5 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023. [PMID: 36626630 DOI: 10.1097/HEP.0000000000000004] [Reference Citation Analysis]
6 Ren Z, Simons PIHG, Wesselius A, Stehouwer CDA, Brouwers MCGJ. Relationship between NAFLD and coronary artery disease: A Mendelian randomization study. Hepatology 2023;77:230-8. [PMID: 35441719 DOI: 10.1002/hep.32534] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
7 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2023;72:141-52. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
8 Shi H, Prough RA, Mcclain CJ, Song M. Different Types of Dietary Fat and Fructose Interactions Result in Distinct Metabolic Phenotypes in Male Mice. The Journal of Nutritional Biochemistry 2023;111:109189. [DOI: 10.1016/j.jnutbio.2022.109189] [Reference Citation Analysis]
9 Yong JN, Lim WH, Ng CH, Tan DJH, Xiao J, Tay PWL, Lin SY, Syn N, Chew N, Nah B, Dan YY, Huang DQ, Tan EXX, Sanyal AJ, Noureddin M, Siddiqui MS, Muthiah MD. Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review. Clin Gastroenterol Hepatol 2023;21:45-54.e6. [PMID: 34801743 DOI: 10.1016/j.cgh.2021.11.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
10 Bataller R, Arab JP, Shah VH. Alcohol-Associated Hepatitis. N Engl J Med 2022;387:2436-48. [PMID: 36577100 DOI: 10.1056/NEJMra2207599] [Reference Citation Analysis]
11 Morkem R, Theal R, Barber D, Flemming J, Queenan J, Kehar M. Screening Patterns of Nonalcoholic Fatty Liver Disease in Children with Obesity in Canadian Primary Care: A Cross-Sectional Study. Can J Gastroenterol Hepatol 2022;2022:8435581. [PMID: 36594051 DOI: 10.1155/2022/8435581] [Reference Citation Analysis]
12 Qadri S, Yki-Järvinen H. The quest for the missing links in fatty liver genetics: Deep learning to the rescue! Cell Rep Med 2022;3:100862. [PMID: 36543096 DOI: 10.1016/j.xcrm.2022.100862] [Reference Citation Analysis]
13 Gawrieh S, Karns R, Kleiner DE, Olivier M, Jenkins T, Inge TH, Chalasani NP, Xanthakos S. Comparative Analysis of Global Hepatic Gene Expression in Adolescents and Adults with Non-alcoholic Fatty Liver Disease.. [DOI: 10.1101/2022.12.08.519606] [Reference Citation Analysis]
14 Mak LY, Gane E, Schwabe C, Yoon KT, Heo J, Scott R, Lee JH, Lee JI, Kweon YO, Weltman M, Harrison SA, Neuschwander-Tetri BA, Cusi K, Loomba R, Given BD, Christianson DR, Garcia-Medel E, Yi M, Hamilton J, Yuen MF. A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis. J Hepatol 2022:S0168-8278(22)03320-7. [PMID: 36513186 DOI: 10.1016/j.jhep.2022.11.025] [Reference Citation Analysis]
15 Pibiri M, Simbula G. Role of the Hippo pathway in liver regeneration and repair: recent advances. Inflamm Regen 2022;42:59. [PMID: 36471376 DOI: 10.1186/s41232-022-00235-5] [Reference Citation Analysis]
16 Vieira Alves VP, Qiu L, Abu-El-Haija M, Tellez S, Vitale DS, Lin TK, Tkach JA, Nathan JD, Dillman JR, Trout AT. Prospective characterization of incident hepatic steatosis in pediatric and adolescent patients after total pancreatectomy with islet autotransplantation. Pancreatology 2022;22:1175-80. [PMID: 36198489 DOI: 10.1016/j.pan.2022.09.242] [Reference Citation Analysis]
17 Younossi ZM, Harring M, Younossi Y, Ong JP, Alqahtani SA, Stepanova M. The Impact of NASH to Liver Transplantations With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol 2022;20:2915-2917.e1. [PMID: 34666156 DOI: 10.1016/j.cgh.2021.10.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Ventura-Cots M, Bataller R, Lazarus JV, Benach J, Pericàs JM. Applying an equity lens to liver health and research in Europe. J Hepatol 2022;77:1699-710. [PMID: 35985542 DOI: 10.1016/j.jhep.2022.07.021] [Reference Citation Analysis]
19 Plaz Torres MC, Jaffe A, Perry R, Marabotto E, Strazzabosco M, Giannini EG. Diabetes medications and risk of HCC. Hepatology 2022;76:1880-97. [PMID: 35239194 DOI: 10.1002/hep.32439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
20 Han H, Jin W, Li X. Mesenchymal stem cells-based therapy in liver diseases. Mol Biomed 2022;3:23. [DOI: 10.1186/s43556-022-00088-x] [Reference Citation Analysis]
21 Holmer M, Hagström H, Chen P, Danielsson O, Aouadi M, Rydén M, Stål P. Associations between subcutaneous adipocyte hypertrophy and nonalcoholic fatty liver disease. Sci Rep 2022;12:20519. [PMID: 36443373 DOI: 10.1038/s41598-022-24482-1] [Reference Citation Analysis]
22 Jiao J, Sanchez JI, Saldarriaga OA, Solis LM, Tweardy DJ, Maru DM, Stevenson HL, Beretta L. Spatial molecular and cellular determinants of STAT3 activation in liver fibrosis progression in non-alcoholic fatty liver disease. JHEP Rep 2023;5:100628. [PMID: 36687470 DOI: 10.1016/j.jhepr.2022.100628] [Reference Citation Analysis]
23 Cheng XS, VanWagner LB, Costa SP, Axelrod DA, Bangalore S, Norman SP, Herzog CA, Lentine KL; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Cardiovascular Radiology and Intervention. Emerging Evidence on Coronary Heart Disease Screening in Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association: Endorsed by the American Society of Transplantation. Circulation 2022;146:e299-324. [PMID: 36252095 DOI: 10.1161/CIR.0000000000001104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gao F, Lu D, Zheng T, Geng S, Sha J, Huang O, Tang L, Zhu P, Li Y, Chen L, Targher G, Byrne CD, Huang Z, Zheng M, CHESS-MAFLD consortium. Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identifies non-alcoholic steatohepatitis. Hepatol Int 2022. [DOI: 10.1007/s12072-022-10444-2] [Reference Citation Analysis]
25 Villeret F, Dharancy S, Erard D, Abergel A, Barbier L, Besch C, Boillot O, Boudjema K, Coilly A, Conti F, Corpechot C, Duvoux C, Faitot F, Faure S, Francoz C, Giostra E, Gugenheim J, Hardwigsen J, Hilleret MN, Hiriart JB, Houssel-Debry P, Kamar N, Lassailly G, Latournerie M, Pageaux GP, Samuel D, Vanlemmens C, Saliba F, Dumortier J. Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival. Liver Int 2022;42:2428-41. [PMID: 35924452 DOI: 10.1111/liv.15385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Welles JE, Lacko H, Kawasawa YI, Dennis MD, Jefferson LS, Kimball SR. An integrative approach to assessing effects of a short-term Western diet on gene expression in rat liver. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1032293] [Reference Citation Analysis]
27 Brawley OW. Cancer Screening and Early Detection. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm039.pub2] [Reference Citation Analysis]
28 P V Alves V, Trout AT, Dewit M, Mouzaki M, Arce-Clachar AC, S Bramlage K, Dillman JR, A Xanthakos S. Clinical Performance of Transient Elastography with Comparison to Quantitative Magnetic Resonance Imaging, Ultrasound, and Biopsy in Children and Adolescents with Known or Suspected Fatty Liver Disease. Child Obes 2022. [PMID: 36269577 DOI: 10.1089/chi.2022.0136] [Reference Citation Analysis]
29 Jacobson IM, Wong VW, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM. Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2022. [PMID: 36251413 DOI: 10.1097/MCG.0000000000001780] [Reference Citation Analysis]
30 Dufour JF, Anstee QM, Bugianesi E, Harrison S, Loomba R, Paradis V, Tilg H, Wong VW, Zelber-Sagi S. Current therapies and new developments in NASH. Gut 2022;71:2123-34. [PMID: 35710299 DOI: 10.1136/gutjnl-2021-326874] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
31 Younossi ZM, Yilmaz Y, Yu ML, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M, Kugelmas M, Ong JP, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry. Clin Gastroenterol Hepatol 2022;20:2296-2306.e6. [PMID: 34768009 DOI: 10.1016/j.cgh.2021.11.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 9.0] [Reference Citation Analysis]
32 Kim D, Alshuwaykh O, Dennis BB, Cholankeril G, Ahmed A. Trends in Etiology-based Mortality From Chronic Liver Disease Before and During COVID-19 Pandemic in the United States. Clin Gastroenterol Hepatol 2022;20:2307-2316.e3. [PMID: 35811045 DOI: 10.1016/j.cgh.2022.05.045] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Le MH, Yeo YH, Zou B, Barnet S, Henry L, Cheung R, Nguyen MH. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin Mol Hepatol 2022;28:841-50. [PMID: 36117442 DOI: 10.3350/cmh.2022.0239] [Reference Citation Analysis]
34 Sporea I, Lupușoru R, Șirli R. Ultrasound Based Elastography Techniques for the Evaluation of Nonalcoholic Liver Disease. Elastography - Applications in Clinical Medicine 2022. [DOI: 10.5772/intechopen.102363] [Reference Citation Analysis]
35 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers 2022;14:4651. [DOI: 10.3390/cancers14194651] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Chhatwal J, Dalgic OO, Chen W, Samur S, Bethea ED, Xiao J, Hur C, Corey KE, Loomba R. Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2022;5:e2230426. [PMID: 36098969 DOI: 10.1001/jamanetworkopen.2022.30426] [Reference Citation Analysis]
37 Kim RG, Chu JN, Vittinghoff E, Deng J, Reaso JN, Grenert JP, Khalili M. Racial/ethnic differences in fibrosis prevalence and progression in biopsy-proven steatosis: A focus on the Asian American population. Hepatol Commun 2022;6:3024-35. [PMID: 36087033 DOI: 10.1002/hep4.2078] [Reference Citation Analysis]
38 Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology 2022. [PMID: 36082510 DOI: 10.1002/hep.32779] [Reference Citation Analysis]
39 Bassegoda O, Rivera-Esteban J, Serra I, Morillas R, Broquetas T, Vergara M, Rodriguez A, Aracil C, Virolés S, Carrión JA, Pardo A, Rodríguez-Tajes S, Serra-Burriel M, Pericàs JM, Augustin S, Ginès P, Graupera I. High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study. Hepatol Commun 2022;6:3212-22. [PMID: 36073343 DOI: 10.1002/hep4.2056] [Reference Citation Analysis]
40 Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, Sookoian S, Wong VW. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology 2022. [PMID: 36062393 DOI: 10.1002/hep.32774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther 2022;56:942-56. [PMID: 35880713 DOI: 10.1111/apt.17158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
42 Eeckhoute J. Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States. Cells 2022;11:2551. [DOI: 10.3390/cells11162551] [Reference Citation Analysis]
43 Tian-Qi C, Yan-Fang D, Yan-Yan W, Yong-Hui Z. Butyrolactone I attenuates inflammation in murine NASH by inhibiting the NF-κB signaling pathway. Biochem Biophys Res Commun 2022;626:167-74. [PMID: 35994826 DOI: 10.1016/j.bbrc.2022.07.050] [Reference Citation Analysis]
44 Li DD, Ma JM, Li MJ, Gao LL, Fan YN, Zhang YN, Tao XJ, Yang JJ. Supplementation of Lycium barbarum Polysaccharide Combined with Aerobic Exercise Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis via AMPK/PPARα/PGC-1α Pathway. Nutrients 2022;14:3247. [PMID: 35956423 DOI: 10.3390/nu14153247] [Reference Citation Analysis]
45 Pérez-mayorga M, Lopez-lopez JP, Chacon-manosalva MA, Castillo MG, Otero J, Martinez-bello D, Gomez-arbelaez D, Cohen DD, Lopez-jaramillo P, Ravaioli F. Insulin Resistance Markers to Detect Nonalcoholic Fatty Liver Disease in a Male Hispanic Population. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-7. [DOI: 10.1155/2022/1782221] [Reference Citation Analysis]
46 Baratta F, D'erasmo L, Bini S, Pastori D, Angelico F, Del Ben M, Arca M, Di Costanzo A. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Marie S, Frost KL, Hau RK, Martinez-guerrero L, Izu JM, Myers CM, Wright SH, Cherrington NJ. Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.08.018] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Lonardo A, Mantovani A, Petta S, Carraro A, Byrne CD, Targher G. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. Nat Rev Endocrinol 2022. [PMID: 35840803 DOI: 10.1038/s41574-022-00711-5] [Reference Citation Analysis]
49 Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: An updated meta-analysis and systematic review. Int J Surg 2022;104:106752. [PMID: 35803515 DOI: 10.1016/j.ijsu.2022.106752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Raz Bhutto S, Wu Y, Zeng M, Wahab Dogar A, Ullah K, Li M. DRCNNTLe: A deep recurrent convolutional neural network with transfer learning through pre-trained embeddings for automated ICD coding. Methods 2022:S1046-2023(22)00142-6. [PMID: 35781051 DOI: 10.1016/j.ymeth.2022.06.004] [Reference Citation Analysis]
51 Ramanathan R, Ali AH, Ibdah JA. Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease. IJMS 2022;23:7280. [DOI: 10.3390/ijms23137280] [Reference Citation Analysis]
52 Martínez-urbistondo D, San Cristóbal R, Villares P, Martínez-gonzález MÁ, Babio N, Corella D, del Val JL, Ordovás JM, Alonso-gómez ÁM, Wärnberg J, Vioque J, Romaguera D, López-miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra-majem JL, Bueno-cavanillas A, Tur JA, Marcos A, Pintó X, Delgado-rodríguez M, Matía-martín P, Vidal J, Vázquez C, Ros E, Bullón Vela MV, Palau A, Masagué M, Abete I, Moreno-rodríguez A, Candela-garcía I, Konieczna J, García-ríos A, Juárez OL, Martín P, Goday A, Zulet MÁ, Vaquero-luna J, Orea MDCS, Megías I, Baltasar E, Martínez JA, Daimiel L. Role of NAFLD on the Health Related QoL Response to Lifestyle in Patients With Metabolic Syndrome: The PREDIMED Plus Cohort. Front Endocrinol 2022;13:868795. [DOI: 10.3389/fendo.2022.868795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Subramanian P, Hampe J, Tacke F, Chavakis T. Fibrogenic Pathways in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD). IJMS 2022;23:6996. [DOI: 10.3390/ijms23136996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Yang X, Jeong K, Yabes JG, Ragni MV. Prevalence and risk factors for hepatocellular carcinoma in individuals with haemophilia in the era of direct-acting antiviral agents: A national inpatient sample study. Haemophilia 2022. [PMID: 35727998 DOI: 10.1111/hae.14607] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Johansen MJ, Vonsild Lund MA, Ängquist L, Fonvig CE, Holm LA, Chabanova E, Thomsen HS, Hansen T, Holm JC. Possible prediction of obesity-related liver disease in children and adolescents using indices of body composition. Pediatr Obes 2022;:e12947. [PMID: 35726748 DOI: 10.1111/ijpo.12947] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 McGlone ER, Ansell TB, Dunsterville C, Song W, Carling D, Tomas A, Bloom SR, Sansom MSP, Tan T, Jones B. Hepatocyte cholesterol content modulates glucagon receptor signalling. Mol Metab 2022;:101530. [PMID: 35718339 DOI: 10.1016/j.molmet.2022.101530] [Reference Citation Analysis]
57 Julià H, Benaiges D, Pedro-botet J. Bariatric surgery and non-alcoholic fatty liver disease. Medicina Clínica (English Edition) 2022;158:550-555. [DOI: 10.1016/j.medcle.2022.05.009] [Reference Citation Analysis]
58 Younossi Z, Aggarwal P, Shrestha I, Fernandes J, Johansen P, Augusto M, Nair S. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Hassen G, Singh A, Belete G, Jain N, De la Hoz I, Camacho-leon GP, Dargie NK, Carrera KG, Alemu T, Jhaveri S, Solomon N. Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease. Cureus. [DOI: 10.7759/cureus.25495] [Reference Citation Analysis]
60 So WZ, Tan FL, Tan DJH, Ng CH, Yong JN, Syn N, Tang ASP, Wong RC, Lin W, Tan EXX, Huang DQ, Dan YY, Chew NWS, Siddiqui MS, Muthiah MD. A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation. Dig Liver Dis 2022;54:614-21. [PMID: 34896025 DOI: 10.1016/j.dld.2021.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
61 Umemura A, Kataoka S, Okuda K, Seko Y, Yamaguchi K, Moriguchi M, Okanoue T, Itoh Y. Potential Therapeutic Targets and Promising Agents for Combating NAFLD. Biomedicines 2022;10:901. [DOI: 10.3390/biomedicines10040901] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Xiao J, Yong JN, Ng CH, Syn N, Lim WH, Tan DJH, Tan EY, Huang D, Wong RC, Chew NWS, Tan EXX, Noureddin M, Siddiqui MS, Muthiah MD. A Meta-Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients. Liver Transpl 2022;28:689-99. [PMID: 34626045 DOI: 10.1002/lt.26331] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
63 Younossi Z, Henry L. Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences. EMJ Hepatol 2022. [DOI: 10.33590/emjhepatol/22-00150] [Reference Citation Analysis]
64 Lieber SR, Kim HP, Baldelli L, Nash R, Teal R, Magee G, Desai CS, Loiselle MM, Lee SC, Singal AG, Marrero JA, Barritt AS 4th, Evon DM. Early Survivorship After Liver Transplantation: A Qualitative Study Identifying Challenges in Recovery From the Patient and Caregiver Perspective. Liver Transpl 2022;28:422-36. [PMID: 34529886 DOI: 10.1002/lt.26303] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA, Loomba R, Sanyal AJ, Bonacci M, Trylesinski A, Natha M, Shringarpure R, Granston T, Venugopal A, Ratziu V. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol 2022;76:536-48. [PMID: 34793868 DOI: 10.1016/j.jhep.2021.10.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
66 Stepanova M, Kabbara K, Mohess D, Verma M, Roche‐green A, Alqahtani S, Ong J, Burra P, Younossi ZM. Nonalcoholic steatohepatitis is the most common indication for liver transplantation among the elderly: Data from the United States Scientific Registry of Transplant Recipients. Hepatology Communications. [DOI: 10.1002/hep4.1915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Schwartz S, Lucas J, DeLegge MH. Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. touchREV Endocrinol 2021;17:112-20. [PMID: 35118457 DOI: 10.17925/EE.2021.17.2.112] [Reference Citation Analysis]
68 Julià H, Benaiges D, Pedro-botet J. Bariatric surgery and non-alcoholic fatty liver disease. Medicina Clínica 2022. [DOI: 10.1016/j.medcli.2021.12.003] [Reference Citation Analysis]
69 Sebastiani G, Patel K, Ratziu V, Feld JJ, Neuschwander-tetri BA, Pinzani M, Petta S, Berzigotti A, Metrakos P, Shoukry N, Brunt EM, Tang A, Cobbold JF, Ekoe J, Seto K, Ghali P, Chevalier S, Anstee QM, Watson H, Bajaj H, Stone J, Swain MG, Ramji A. Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). CanLivJ 2022;5:61-90. [DOI: 10.3138/canlivj-2021-0030] [Reference Citation Analysis]
70 Servin‐rojas M, Olivas‐martinez A, Toapanta‐yanchapaxi L, García‐juárez I. Liver Transplantation in Mexico. Clinical Liver Disease. [DOI: 10.1002/cld.1155] [Reference Citation Analysis]
71 Bardales Silva AF. Enfermedad hepática grasa relacionada a trastornos metabólicos. RMB 2022;15:85-93. [DOI: 10.33326/26176068.2021.4.1259] [Reference Citation Analysis]
72 Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:180-91. [PMID: 35027111 DOI: 10.1016/j.jacc.2021.11.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
73 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules 2022;12:105. [DOI: 10.3390/biom12010105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
74 Ciardullo S, Pizzi M, Pizzi P, Oltolini A, Muraca E, Perseghin G. Prevalence of Elevated Liver Stiffness Among Potential Candidates for Bariatric Surgery in the United States. Obes Surg 2022;32:712-9. [PMID: 34988895 DOI: 10.1007/s11695-021-05885-x] [Reference Citation Analysis]
75 Garbuzenko DV. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;31:16-24. [DOI: 10.22416/1382-4376-2021-31-5-16-24] [Reference Citation Analysis]
76 Govaere O, Anstee QM. Non-Alcoholic Fatty Liver Disease and Steatohepatitis. Reference Module in Life Sciences 2022. [DOI: 10.1016/b978-0-12-821618-7.00265-0] [Reference Citation Analysis]
77 Gao F, He Q, Li G, Huang OY, Tang LJ, Wang XD, Targher G, Byrne CD, Luo JW, Zheng MH. A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. Liver Int 2022;42:80-91. [PMID: 34564946 DOI: 10.1111/liv.15064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
78 Koeckerling D, Marjot T, Cobbold J. Non-alcoholic Fatty Liver Disease. In Clinical Practice 2022. [DOI: 10.1007/978-3-031-10012-3_7] [Reference Citation Analysis]
79 Vieira Barbosa J, Milligan S, Frick A, Broestl J, Younossi Z, Afdhal NH, Lai M. Fibrosis-4 Index as an Independent Predictor of Mortality and Liver-Related Outcomes in NAFLD. Hepatol Commun 2021. [PMID: 34970870 DOI: 10.1002/hep4.1841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
80 Han MAT, Olivo R, Choi CJ, Pyrsopoulos N. De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation. World J Hepatol 2021; 13(12): 1991-2004 [DOI: 10.4254/wjh.v13.i12.1991] [Reference Citation Analysis]
81 Choi YS, Beltran TA, Calder SA, Padilla CR, Berry-Cabán CS, Salyer KR. Prevalence of Hepatic Steatosis and Fibrosis in the United States. Metab Syndr Relat Disord 2021. [PMID: 34962146 DOI: 10.1089/met.2021.0111] [Reference Citation Analysis]
82 Rajapaksha IG, Gunarathne LS, Asadi K, Laybutt R, Andrikopoulous S, Alexander IE, Watt MJ, Angus PW, Herath CB. Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver. Hepatology Communications. [DOI: 10.1002/hep4.1884] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Lazebnik LB, Turkina SV. NAFLD Associated Comorbidity. jour 2021. [DOI: 10.31146/1682-8658-ecg-194-10-5-13] [Reference Citation Analysis]
84 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
85 Venkateswaran N, Weismiller S, Krok K. Recurrent NASH Post-liver Transplant: Implications and Treatment. Curr Hepatology Rep 2021;20:108-116. [DOI: 10.1007/s11901-021-00569-7] [Reference Citation Analysis]
86 Zhou H, Tullius SG. Effects of obesity and weight-loss surgery shift the microbiome and impact alloimmune responses. Curr Opin Organ Transplant 2021;26:603-8. [PMID: 34714789 DOI: 10.1097/MOT.0000000000000920] [Reference Citation Analysis]
87 Shen B, Wang J, Guo Y, Gu T, Shen Z, Zhou C, Li B, Xu X, Li F, Zhang Q, Cai X, Dong H, Lu L. Dextran Sulfate Sodium Salt-Induced Colitis Aggravates Gut Microbiota Dysbiosis and Liver Injury in Mice With Non-alcoholic Steatohepatitis. Front Microbiol 2021;12:756299. [PMID: 34795650 DOI: 10.3389/fmicb.2021.756299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
88 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Tripathi M, Gauthier K, Sandireddy R, Zhou J, Arul K, Tikno K, Park S, Wu Y, Bay B, Giguere V, Chow PKH, Mcdonnell DP, Yen PM, Singh BK. Estrogen-related receptor alpha and Rplp1-dependent translation coordinately regulate starvation response and decrease NASH progression.. [DOI: 10.1101/2021.11.16.468891] [Reference Citation Analysis]
90 Roberts SK, Majeed A. A short report on NGM282/aldafermin for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Ther Targets 2021;25:889-95. [PMID: 34727818 DOI: 10.1080/14728222.2021.1999416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
91 Mathur K, Mazhar A, Patel M, Dakhoul L, Burney H, Liu H, Nephew L, Chalasani N, deLemos A, Gawrieh S. Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. Clin Transl Gastroenterol 2021;12:e00420. [PMID: 34730559 DOI: 10.14309/ctg.0000000000000420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
92 Mcglone ER, Ansell TB, Dunsterville C, Song W, Carling D, Tomas A, Bloom SR, Sansom MSP, Tan T, Jones B. Hepatocyte cholesterol content modulates glucagon receptor signalling.. [DOI: 10.1101/2021.10.31.466084] [Reference Citation Analysis]
93 Homkrailas P, Ayoub WS, Martin P, Bunnapradist S. Kidney utilization and outcomes of liver transplant recipients who were listed for kidney after liver transplant after the implementation of safety net policy. Clin Transplant 2021;:e14522. [PMID: 34716954 DOI: 10.1111/ctr.14522] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Musto J, Spengler EK, German MN. Sexual Dimorphisms in Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2021;20:97-107. [DOI: 10.1007/s11901-021-00568-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Majzoub AM, Nayfeh T, Barnard A, Munaganuru N, Dave S, Singh S, Murad MH, Loomba R. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. Aliment Pharmacol Ther 2021;54:880-9. [PMID: 34435378 DOI: 10.1111/apt.16583] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
97 Arshad T, Paik JM, Biswas R, Alqahtani SA, Henry L, Younossi ZM. Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007-2016. Hepatol Commun 2021;5:1676-88. [PMID: 34558817 DOI: 10.1002/hep4.1760] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
98 Hui ST, Wang F, Stappenbeck F, French SW, Magyar CE, Parhami F, Lusis AJ. Oxy210, a novel inhibitor of hedgehog and TGF-β signalling, ameliorates hepatic fibrosis and hypercholesterolemia in mice. Endocrinol Diabetes Metab 2021;4:e00296. [PMID: 34505423 DOI: 10.1002/edm2.296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
99 Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, Piercy DL, Seymour KA, Sudan R, Portenier DD, Diehl AM, Coviello AD, Abdelmalek MF. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology 2021;74:1220-33. [PMID: 33724511 DOI: 10.1002/hep.31806] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
100 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH Epidemic: A Call to Action. Gastroenterology 2021;161:1030-1042.e8. [PMID: 34416976 DOI: 10.1053/j.gastro.2021.04.074] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
101 Holland CH, Ramirez Flores RO, Myllys M, Hassan R, Edlund K, Hofmann U, Marchan R, Cadenas C, Reinders J, Hoehme S, Seddek AL, Dooley S, Keitel V, Godoy P, Begher-Tibbe B, Trautwein C, Rupp C, Mueller S, Longerich T, Hengstler JG, Saez-Rodriguez J, Ghallab A. Transcriptomic Cross-Species Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice. Hepatol Commun 2021. [PMID: 34558834 DOI: 10.1002/hep4.1797] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
102 Younossi ZM, Stepanova M, Lam B, Cable R, Felix S, Jeffers T, Younossi E, Pham H, Srishord M, Austin P, Estep M, Terra K, Escheik C, de Avila L, Golabi P, Kolacevski A, Racila A, Henry L, Gerber L. Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection. Hepatol Commun 2022;6:3062-72. [PMID: 34558853 DOI: 10.1002/hep4.1802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
103 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring) 2021;29:1401-12. [PMID: 34365735 DOI: 10.1002/oby.23250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
104 Pereira ENGDS, Paula DP, Araujo BP, Fonseca MJMD, Diniz MFHS, Daliry A, Griep RH. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol 2021; 27(29): 4913-4928 [PMID: 34447235 DOI: 10.3748/wjg.v27.i29.4913] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
105 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
106 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Metabolism 2021;122:154822. [PMID: 34289945 DOI: 10.1016/j.metabol.2021.154822] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
107 Waits SA, Parikh ND. Edging Closer to Commonplace: Assessing the Growth of Living Donor Liver Transplantation in the United States. Liver Transpl 2021;27:959-60. [PMID: 33887807 DOI: 10.1002/lt.26077] [Reference Citation Analysis]
108 Alqahtani SA, Paik JM, Biswas R, Arshad T, Henry L, Younossi ZM. Poor Awareness of Liver Disease Among Adults With NAFLD in the United States. Hepatol Commun. [DOI: 10.1002/hep4.1765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
109 Alqahtani SA, Broering DC, Alghamdi SA, Bzeizi KI, Alhusseini N, Alabbad SI, Albenmousa A, Alfaris N, Abaalkhail F, Al-Hamoudi WK. Changing trends in liver transplantation indications in Saudi Arabia: from hepatitis C virus infection to nonalcoholic fatty liver disease. BMC Gastroenterol 2021;21:245. [PMID: 34074270 DOI: 10.1186/s12876-021-01828-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
110 Kwong AJ, Kim WR. Predicting Survival After Liver Transplantation: A Noble Pursuit or a Fool's Errand? Liver Transpl 2021;27:789-90. [PMID: 33773023 DOI: 10.1002/lt.26057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Stepanova M, Younossi Z. Reply. Clin Gastroenterol Hepatol 2021;19:1299-300. [PMID: 33248088 DOI: 10.1016/j.cgh.2020.07.038] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
112 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
113 Deng Y, Ma J, Weng X, Wang Y, Li M, Yang T, Dou Z, Yin Z, Shang J. Kaempferol-3-O-Glucuronide Ameliorates Non-Alcoholic Steatohepatitis in High-Cholesterol-Diet-Induced Larval Zebrafish and HepG2 Cell Models via Regulating Oxidation Stress. Life (Basel) 2021;11:445. [PMID: 34069176 DOI: 10.3390/life11050445] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep 2021;3:100305. [PMID: 34189448 DOI: 10.1016/j.jhepr.2021.100305] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 15.5] [Reference Citation Analysis]
115 Gor R, Siddiqui NA, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Malik M, Hamid P. Unraveling the Role of Hypothyroidism in Non-alcoholic Fatty Liver Disease Pathogenesis: Correlations, Conflicts, and the Current Stand. Cureus 2021;13:e14858. [PMID: 34104598 DOI: 10.7759/cureus.14858] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021; 27(16): 1691-1715 [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
117 Ciardullo S, Muraca E, Zerbini F, Manzoni G, Perseghin G. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. J Clin Endocrinol Metab 2021;106:e2856-65. [PMID: 33878156 DOI: 10.1210/clinem/dgab262] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
118 Nitski O, Azhie A, Qazi-Arisar FA, Wang X, Ma S, Lilly L, Watt KD, Levitsky J, Asrani SK, Lee DS, Rubin BB, Bhat M, Wang B. Long-term mortality risk stratification of liver transplant recipients: real-time application of deep learning algorithms on longitudinal data. Lancet Digit Health 2021;3:e295-305. [PMID: 33858815 DOI: 10.1016/S2589-7500(21)00040-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
119 Waghorn PA, Ferreira DS, Erstad DJ, Rotile NJ, Masia R, Jones CM, Tu C, Sojoodi M, Chen YI, Schlerman F, Wellen J, Martinez RVP, Tanabe KK, Fuchs BC, Caravan P. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. Sci Rep 2021;11:6105. [PMID: 33731798 DOI: 10.1038/s41598-021-85679-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Romano DN, Mokuolu DC, Katz DJ, DeMaria S Jr. Orthotopic liver transplant in the pregnant recipient: A systematic review of preoperative management and maternal and fetal outcomes. Clin Transplant 2021;35:e14269. [PMID: 33615548 DOI: 10.1111/ctr.14269] [Reference Citation Analysis]
121 Gariani K, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. Endocr Connect 2021;10:R52-65. [PMID: 33449917 DOI: 10.1530/EC-20-0490] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
122 Zhu C, Tabas I, Schwabe RF, Pajvani UB. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis. Nat Rev Gastroenterol Hepatol 2021;18:131-42. [PMID: 33051603 DOI: 10.1038/s41575-020-00365-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 18.0] [Reference Citation Analysis]
123 Paik JM, Golabi P, Younossi Y, Saleh N, Nhyira A, Younossi ZM. The Growing Burden of Disability Related to Chronic Liver Disease in the United States: Data From the Global Burden of Disease Study 2007-2017. Hepatol Commun 2021;5:749-59. [PMID: 34027266 DOI: 10.1002/hep4.1673] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
124 Garbuzenko D. Non-invasive diagnosis of liver fibrosis associated with nonalcoholic steatohepatitis. Dok gastroenterol 2021;10:75. [DOI: 10.17116/dokgastro20211004175] [Reference Citation Analysis]
125 Han MAT, Yu Q, Tafesh Z, Pyrsopoulos N. Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally. J Clin Transl Hepatol 2021;9:71-80. [PMID: 33604257 DOI: 10.14218/JCTH.2020.00082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
126 Komori A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol 2021;27:58-69. [PMID: 33291862 DOI: 10.3350/cmh.2020.0189] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]